Adamas Announces Final Results from the Two-Year Phase 3 Open-Label Study of GOCOVRIâ„¢ in Parkinson's Disease Patients with Dyskinesia

Author's Avatar
Apr 19, 2018
Article's Main Image

-- Patients receiving GOCOVRI experienced long-term durability for up to two years --